Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Appointed director
Quarterly results
ENANTA PHARMACEUTICALS INC (ENTA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 SC 13G/A BlackRock Inc. reports a 9.4% stake in ENANTA PHARMACEUTICALS INC
08/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 1study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus ; Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Marketable Securities Totaled $392.5 Million at June 30, 2023 • Royalty Revenue for the Quarter was $18.9 Million"
06/07/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "PRODUCT CANDIDATE DISCOVERY PRECLINICAL PHASE 1 PHASE 2 PHASE 3 MARKET"
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19 • Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million • On Track to Report Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus, in June • Royalty Revenue for the Quarter was $17.8 Million"
04/27/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"TABLE OF CONTENTS",
"Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET ® /MAVIRET ® to OMERS Life Sciences for $200 Million"
03/10/2023 8-K Regulation FD Disclosure  Interactive Data
03/07/2023 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits  Interactive Data
Docs: "ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan 1. Purpose The purpose of this 2019 Equity Incentive Plan of Enanta Pharmaceuticals, Inc., a Delaware corporation , is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424 or of the Internal Revenue Code of..."
02/14/2023 SC 13G/A FIRST MANHATTAN CO reports a 1.2% stake in Enanta Pharmaceuticals, Inc.
02/14/2023 SC 13G ARMISTICE CAPITAL, LLC reports a 10% stake in ENANTA PHARMACEUTICALS, INC.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.3% stake in Enanta Pharmaceuticals Inc.
02/08/2023 10-Q Quarterly Report for the period ended December 31, 2022
02/08/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 8-K Quarterly results
Docs: "Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET • Completes Enrollment in SPRINT, a Phase 2 Clinical Study of EDP-235, a 3CL Protease Inhibitor Designed as an Oral, Once-Daily Treatment for COVID-19; Topline Data Expected in May • Expects Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus , in 2Q 2023 • Expands Robust Pipeline with New Research Programs Developing SARS-CoV-2 Papain-Like Protease Inhibitors and Human Metapneumovirus /RSV Dual-Inhibitors • Revenue for the Quarter was $23.6 Million"
02/07/2023 ARS Form ARS - Annual Report to Security Holders:
02/06/2023 SC 13G/A Farallon Capital Partners, L.P. reports a 7.5% stake in Enanta Pharmaceuticals, Inc.
01/31/2023 SC 13G BlackRock Inc. reports a 18% stake in ENANTA PHARMACEUTICALS INC
01/20/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
01/20/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
11/23/2022 10-K Annual Report for the period ended September 30, 2022
11/21/2022 8-K Quarterly results
08/26/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Open Market Sale AgreementSM dated August 26, 2022, by and between Enanta Pharmaceuticals, Inc. and Jefferies LLC",
"Opinion of Foley Hoag LLP"
08/26/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
08/08/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/08/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
05/17/2022 8-K Quarterly results
05/09/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 8-K Quarterly results
03/09/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy